These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16035285)

  • 1. [Prevention of type 1 diabetes: interventions in mice and in humans].
    Mathieu C; Keymeulen B
    Rev Med Liege; 2005; 60(5-6):303-5. PubMed ID: 16035285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials for the prevention of type 1 diabetes.
    Chase HP; Hayward AR; Eisenbarth GS
    Adv Exp Med Biol; 2004; 552():291-305. PubMed ID: 15622969
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune intervention with anti-CD3 in diabetes.
    Harlan DM; von Herrath M
    Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of type 1 diabetes: where do we start?
    Pozzilli P; Adorini L
    J Endocrinol Invest; 2003 Apr; 26(4):292-3. PubMed ID: 12841534
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical studies. Trying to reset the clock on type 1 diabetes.
    Couzin-Frankel J
    Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we change the course of beta-cell destruction in type 1 diabetes?
    Gale EA
    N Engl J Med; 2002 May; 346(22):1740-2. PubMed ID: 12037155
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of type 1 diabetes: today and tomorrow.
    Cernea S; Dobreanu M; Raz I
    Diabetes Metab Res Rev; 2010 Nov; 26(8):602-5. PubMed ID: 20936604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Type 1 diabetes: origin and possibilities for prevention].
    Mathieu C; Decallonne B; Casteels K
    Verh K Acad Geneeskd Belg; 2000; 62(5):423-36; discussion 436-7. PubMed ID: 11144689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
    Philips JC; Scheen AJ;
    Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease.
    Bowman MA; Leiter EH; Atkinson MA
    Immunol Today; 1994 Mar; 15(3):115-20. PubMed ID: 8172643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CD3-specific antibody-induced T-cell apoptosis and apoptotic cell uptake lead to CD3-specific antibody-induced tolerance].
    Perruche S; Saas P
    Med Sci (Paris); 2009 Apr; 25(4):325-7. PubMed ID: 19409176
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
    Chatenoud L
    Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth.
    Roep BO
    Ann N Y Acad Sci; 2007 Apr; 1103():1-10. PubMed ID: 17376838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
    Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
    Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to diabetes disease control, insulin delivery, and monitoring.
    McCarthy AA
    Chem Biol; 2004 Dec; 11(12):1597-8. PubMed ID: 15610839
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention versus intervention of type 1 diabetes.
    Brooks-Worrell B; Palmer JP
    Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anti-CD3 monoclonal antibody delays diabetes in non-obese diabetic (NOD) mice: effects on pregnancy and offspring--a preliminary report.
    Bevier WC; Trujillo AL; Primbs GB; Bradley MK; Jovanovič L
    Diabetes Metab Res Rev; 2011 Jul; 27(5):480-7. PubMed ID: 21484981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Otelixizumab in the treatment of type 1 diabetes mellitus.
    Sprangers B; Van der Schueren B; Gillard P; Mathieu C
    Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.